In yet another unprecedented initiative, the company is recognized as a producer of Reference Material with proven commutativity for Covid-19 Since the beginning of the Covid-19 pandemic, Controllab has made its know-how available as an important ally of the diagnostics sector. The company forerunner SARS-CoV2 External Controls to ensure the analytical accuracy of testing, earning recognition as the world’s first accredited provider for all virus detection methodologies. In addition, it pioneered public performance evaluation reports that helped kit manufacturers and laboratories make decisions about their analytical systems. The company’s vanguard has been consolidated in another initiative: Controllab is the precursor of the Reference Material (RM) for Covid-19 with proven commutativity.
The RM for Covid-19 is intended for IgG and Total antibody identification tests for SARS-CoV2, and can be used for evaluation of Automation and RLT (Remote Laboratory Test) / POC (Point of Care) systems. The RM offer complements the quality control tools, such as the Proficiency Testing and Internal Control, regarding the verification of effectiveness, methodological validation, implementation and selection of analytical systems, in addition to the evaluation of processes. “The RM for Covid-19 with proven commutativity will infuse more confidence into analytical processes. The user has the use of the material as a very important tool to avoid false positive or negative results”, comments Vinícius Dias, manager of Chemical Tests at Controllab.
The importance of commutativity and RM for Covid-19
Commutativity is evidence that the RM has the same behavior as the clinical sample. That is, with the same characteristics, not undergoing significant changes during the material preparation process.